secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001193125-25-025576
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru reports Q1 net loss $8.9M; positive Phase 2b enobosarm data; FC2 business sold for $18M
--------------------------------------------------------------------------------

- Net loss from continuing ops $1.8M ($0.01/sh) vs $7.7M; overall net loss $8.9M ($0.06/sh) vs $8.3M.
- R&D expenses rose to $5.7M from $1.7M; SG&A fell to $5.2M from $6.7M; cash $26.6M at Dec 31, 2024.
- Phase 2b QUALITY study met primary endpoint: 71% relative reduction in lean mass loss (p=0.002) with enobosarm+semaglutide.
- Enobosarm 3mg+semaglutide preserved 99% of lean mass; 62% relative reduction in stair climb power decline (p=0.0066).
- Sold FC2 Female Condom business for $18M; net proceeds ~$12.3M; $9.9M liability extinguished.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312525025576/0001193125-25-025576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312525025576/d935703d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-025576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer